title: The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries.
abstract: BACKGROUND
  Ascitic tumor-infiltrating lymphocytes (TIL) are a potential source of effectors for adoptive immunotherapy.
  
  
  METHODS
  The TIL phenotype was examined by two-color flow cytometry in malignancy-related ascites of 49 patients with different primaries. Interleukin-10 (IL-10) and neopterin were determined in ascitic fluid by enzyme-linked immunoassay.
  
  
  RESULTS
  Malignant melanoma patients had significantly higher CD3(+), CD3(+)CD8(+) and CD3(+)CD95(+), and lower CD3(+)CD4(+) lymphocyte numbers than patients with other primaries. Ovarian cancer patients had higher CD3(+)CD45RO(+), CD8(+)CD28(+), CD19(+)CD86(+), CD19(+) and CD19(+)CD86(+) lymphocyte numbers, and lower NK cell numbers than patients with gastrointestinal and pancreatic primaries. Pretreated patients had significantly lower concentrations of IL-10, lower CD8(+)CD28(+), CD3(+)CD45RA(+), and higher CD3(+)CD80(+) numbers than chemotherapy-naïve patients. Patients with hepatic metastases had lower CD3(+), CD3(+)CD4(+) and CD3(+)CD45RO(+), and higher CD3(+)CD25(+) and NK cell numbers than patients without liver metastases. A substantial number of cells exhibited dendritic cell phenotype. Significant correlations were observed between neopterin and IL-10 concentrations, and numbers of CD8(+)CD28(+) and CD3(+)CD80(+) lymphocytes.
  
  
  CONCLUSIONS
  Some parameters of TIL phenotype differ depending on primary, previous treatment, or the presence of liver metastases. A negative correlation was observed between IL-10 and neopterin, and an opposing effect of local concentrations of IL-10 and neopterin on the numbers of CD8(+)CD28(+) and CD3(+)CD80(+) was noted.
authors.affiliation: Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic. melichar@fnhk.cz
authors.forename: B
authors.initials: B
authors.lastname: Melichar
authors.forename: M
authors.initials: M
authors.lastname: Tousková
authors.forename: J
authors.initials: J
authors.lastname: Tosner
authors.forename: O
authors.initials: O
authors.lastname: Kopecký
mesh_terms: D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D005770:Gastrointestinal Neoplasms / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D016753:Interleukin-10 / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary; D008207:Lymphatic Metastasis; D018655:Lymphocyte Count; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008545:Melanoma / Q000276:immunology; D008875:Middle Aged; D019798:Neopterin / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000276:immunology; D011379:Prognosis; D012878:Skin Neoplasms / Q000276:immunology
chemical_list: D016753:Interleukin-10; D019798:Neopterin